<DOC>
	<DOCNO>NCT02800629</DOCNO>
	<brief_summary>The propose study pilot , double-blind , randomize clinical trial compare galectin-3 inhibition MCP placebo treatment knee osteoarthritis .</brief_summary>
	<brief_title>Blocking Extracellular Galectin-3 Patients With Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Pectin</mesh_term>
	<criteria>1 . Knee pain least one knee half day month prior screen 2 . Xrays show evidence knee osteoarthritis Kellgren Lawrence Score two three , definite osteophyte possible definite joint space narrowing , consistent mild moderate knee osteoarthritis . If knee affect , patient would choose severe knee outcomes assessment . 3 . Willingness maintain stable analgesic regimen throughout study period 1 . Diagnosis fibromyalgia 2 . Presence underlie inflammatory disease affect knee , include Rheumatoid Arthritis , Psoriatic Arthritis , Gout , Pseudogout , inflammatory disease . 3 . Patients give consent exclude , patient speak , read understand English , translate document , consent form , survey . 4 . While supplement consider safe low risk , patient underlie significant cytopenia ( white blood cell count less 4.0 , hemoglobin le 10 , platelet le 100 ) , impaired renal function ( glomerular filtration rate le 60 ) elevate liver enzyme exclude well .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>